Development and validation of an HPLC method for the quantitation of 1,3-dihydroxy-2-methyixanthone in biodegradable nanoparticles

Journal of Chromatographic Science

Volumn 46, Issue 6, 2008, Pages 472-478

  Teixeira, Maribel ^a,b   Afonso, Carlos M M ^a   Pinto, Madalena M M ^a   Barbosa, Carlos Maurício ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 47549098832     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/46.6.472     Document Type: Article

References (30)

1. L.M.M. Vieira and A. Kijjoa. Naturally-occurring xanthones: recent developments. Curr. Med. Chem. 12: 2413-46 (2005).
2. M.E. Sousa and M.M.M. Pinto. Synthesis of xanthones: an overview. Curr. Med. Chem. 12: 2447-79 (2005).
3. M.M.M. Pinto, M.E. Sousa, and M.S.J. Nascimento. Xanthone derivatives: new insights in biological activities. Curr. Med. Chem. 12: 2517-38 (2005).
4. M. Pedro, F. Cerqueira, M.E. Sousa, M.S.J. Nascimento, and M. Pinto. Xanthones as inhibitors of growth of human cancer cell lines and their effects on the proliferation of human lymphocytes in vitro. Bioorg. Med. Chem. 10: 3725-3730 (2002).
5. P. Speiser. Poorly soluble drugs, a challenge in drug delivery. In Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs, R. H. Mu¨ller, S. Benita and B. Bo¨hm, Eds. Scientific Pub., Stuttgard, 1998, pp. 15-19.
6. S. Sweetana and M. J. Akers. Solubility principles and practices for parenteral drug dosage form development. PDA Pharm. Sci. Technol. 50: 330-342 (1996).
7. A. Sanches, J.L. Villa-Jato, and M.J. Alonso. Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin A. Int. J. Pharm. 99: 263-73 (1993).
8. Y.I. Kim, L. Fluckiger, M. Hoffman, I. Lartaud-Idjouadiene, J. Atkinson, and P. Maincent. The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats. Brit. J. Pharmacol. 120: 399-404 (1997).
9. C. Mallard, J. Coudane, I. Rault, and M. Vert. In vitro delivery of a sparingly water soluble compound from PLA50 microparticles. J. Microencapsul. 17: 13-28 (2000).
10. B. Magenheim and S. Benita. Nanoparticle characterization: a comprehensive physicochemical approach. S.T.P. Pharma Sciences 1: 221-41 (1991).
11. P. Couvreur, C. Dubernet, and F. Puisieux. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Biopharm. 41: 2-13 (1995).
12. M.J. Alonso. Nanoparticulate drug carrier technology. In Microparticulate Systems for the Delivery of Proteins and Vaccines. S. Cohen and H. Bernstain, Eds. Marcel Dekker, New York, 1996, pp. 203-42.
13. R. Jain, N.H. Shah, A.W. Malick, and C. Rhodes. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug. Dev. Ind. Pharm. 24: 703-27 (1998).
14. P.J. Lowe and C.S. Temple. Calcitonin and insulin in isobutyl- cyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol. 46: 547-52 (1994).
15. G. Barrat, G. Couarraze, P. Couvreur, C. Dubernet, E. Fattal, R. Gref, D. Labarre, P. Legrand, G. Ponchel, and C. Vauthier. Polymeric micro- and nanoparticles as drug carriers. In Polymeric Biomaterials, S. Dumitriu, Ed. Marcel Dekker, New York, 2002, pp. 753-81.
16. M. Teixeira, F. Cerqueira, C. M. Barbosa, M.S.J. Nascimento, and M. Pinto. Improvement of the inhibitory effect of xanthones on NO production by encapsulation in PLGA nanocapsules. J. Drug Target. 13: 129-35 (2005).
17. European Comission, Ditectorate General III- Industry Pharmaceuticals and cosmetics. Validation of Analytical Procedures: Methodology. The Rules Governing Medicinal Products in European Union, vol. 3A: 107-17 (1998).
18. European Comission, Ditectorate General III- Industry Pharmaceuticals and cosmetics. Validation of Analytical Procedures: Definition and Terminology. The Rules Governing Medicinal Products in European Union, vol. 3A: 119-25 (1998).
19. United States Pharmacopeia 29/NF 24. Validation of Compendial Methods, Section (1225), United States Pharmacopeial Convention, Rockville, Maryland, USA, 2005, pp. 3050-52.
20. M. Pinto and J. Polo´nia. Synthesis of new xanthones. I. Helv. Chim. Acta 57: 2613-17 (1974).
21. H. Fessi, J.P. Devissaguet, F. Puisieux and, C. Thies. Proce´de´ de pre´-paration de syte´mes colloidaux dispersibles d'une substance, sous forme de nanoparticules. French Patent 2608988-A1 (1988).
22. H. Fessi, F. Puisieux, J. Ph. Devissaguet, N. Ammoury, and S. Benita. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55: R1-R4 (1989).
23. M. Teixeira, C.M.M. Afonso, M.M.M. Pinto, and C.M. Barbosa. A validated HPLC method for the assay of xanthone and 3-methoxyxanthone in PLGA nanocapsules. J. Chromatogr. Sci. 41: 371-76 (2003).
24. L.R. Snyder and J.J. Kirkland. Introduction to Modern Liquid Chromatography, 2nd ed. John Wiley & Sons, New York, 1979, pp. 781-23.
25. A. Segall, F. Hormaechea, M. Vitale, V. Perez, and M. T. Pizzorno. Development and validation of a reversed-phase liquid chromatographic method for analysis of estradiol valerate and medroxypro-gesterone acetate in a tablet formulation. J. Pharm. Biomed. Anal. 19: 803-808 (1999).
26. G.A. Shabir. HPLC method development and validation for pharmaceutical analysis. Pharm. Technol. Eur. Mar. 37-49 (2004).
27. M. Teixeira, M.J. Alonso, M.M.M. Pinto, and C.M. Barbosa. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. European Journal of Pharmaceutics and Biopharmaceutics 59: 491-500 (2005).
28. J.M. Barichello, M. Morishita, K. Takayama, and T. Nagai. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev. Ind. Pharm. 25: 471-76 (1999).
29. S. R. Schaffazick, S.S. Guterres, L.L. de Freitas, and A. R. Pohlmann. Physicochemical characterization and stability of the polymeric nanoparticle systems for drug administration. Quim. Nova 26: 726-37 (2003).
30. S.S. Guterres, H. Fessi, G. Barratt, J-P Devissaguet, and F. Puisieux. Poly(D,L-lactide) nanocapsules containing non-steroidal antiinflammatory drugs: gastrointestinal tolerance following intravenous and oral administration. Int. J. Pharm. 113: 57-63 (1995).